跳至主要内容
临床试验/NCT02231931
NCT02231931已完成1 期

Relative Bioavailability of a Single Oral Dose of Digoxin, Furosemide, Metformin, and Rosuvastatin Given Alone and All Together as a Cocktail, and Investigation of the Effect of Increased Doses of Metformin or Furosemide on Relative Bioavailability of the Other Cocktail Compounds in Healthy Male Subjects

Boehringer Ingelheim1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2014年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
24
试验地点
1
主要终点
Digoxin, Metformin, Rosuvastatin: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)

研究概览

简要总结

To investigate the mutual interaction potential of digoxin, furosemide, metformin, and rosuvastatin when given alone or together as a cocktail, and to investigate the effect of high doses of metformin or furosemide on pharmacokinetics of the other cocktail compounds

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

A (Reference 1) Digoxin

Experimental

1 tablet as single dose, fasted

干预措施: Digoxin (Drug)

B (Reference 2) Furosemide

Experimental

oral solution, as single dose, fasted

干预措施: Furosemide (Drug)

C (Reference 3) Metformin hydrochloride

Experimental

1 film-coated tablet as single dose, fasted

干预措施: Metformin hydrochloride (Drug)

D (Reference 4) Rosuvastatin

Experimental

1 film-coated tablet as single dose, fasted

干预措施: Rosuvastatin (Drug)

E (Test) 1

Experimental

Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted

干预措施: Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin (Drug)

F (Test 2)

Experimental

Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (2 film-coated tablets), Rosuvastatin (1 film-coated tablet), fasted

干预措施: Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin (Drug)

G (Test 3)

Experimental

Digoxin (1 tablet), Furosemide (2.0 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted

干预措施: Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin (Drug)

结局指标

主要结局

Digoxin, Metformin, Rosuvastatin: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)

时间窗: up to 96 hours

Furosemide: Cmax (maximum measured concentration of the analyte in plasma)

时间窗: up to 36 hours

Digoxin, Metformin, Rosuvastatin: Cmax (maximum measured concentration of the analyte in plasma)

时间窗: up to 96 hours

Furosemide: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)

时间窗: up to 36 hours

次要结局

  • Digoxin, Metformin, Rosuvastatin: AUC0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(up to 96 hours)
  • Furosemide: AUC0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(up to 36 hours)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验